Oncolytic Virus Immunotherapy Market Growth, Size, Trends Analysis - By Virus Type, By Application, By Route of Administration, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Description
Oncolytic Virus Immunotherapy Market Introduction and Overview
According to SPER market research, ‘Global Oncolytic Virus Immunotherapy Market Size- By Virus Type, By Application, By Route of Administration, By End-User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Oncolytic Virus Immunotherapy Market is predicted to reach 2945.34 million by 2034 with a CAGR of 22.85%.
Oncolytic virus immunotherapy refers to the use of viruses in the treatment of cancer, aiming to infect and destroy cells that are affected by the disease. Consequently, the naturally occurring virus is engineered to deliver therapeutic payloads to tumors and provide immune-boosting molecules once tumor cells have been infected. The benefits of oncolytic virus immunotherapy include a reduction in tumor burden through virus replication within tumorous cells.
Restraints:
The substantial expenses associated with oncolytic virus therapy are a critical obstacle impeding the expansion of the global oncolytic virus therapy market. The creation of such therapies necessitates extensive research and prolonged clinical trials, rendering the process exceedingly costly. A significant portion of these expenses arises from the various phases of clinical trials aimed at assessing the efficacy and safety of these therapies in human participants.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered
By Virus Type, By Application, By Route of Administration, By End-User
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Amgen Inc, Creative Biolabs, Daiichi Sankyo Company Limited, Genelux Corporation, Oncorus Inc, Replimune Inc, Siga Technologies, Sorrento Therapeutics Inc, TILT Biotherapeutics, Viralytics Ltd.
Global Oncolytic Virus Immunotherapy Market Segmentation:
By Virus Type:
Based on the Virus Type, Global Oncolytic Virus Immunotherapy Market is segmented as; Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Newcastle Disease Virus, Reovirus, Other Virus Type.
By Route of Administration:
Based on the Route of Administration, Global Oncolytic Virus Immunotherapy Market is segmented as; Intratumoral, Intravenous, Other Routes of Administration.
By Application:
Based on the Application, Global Oncolytic Virus Immunotherapy Market is segmented as; Melanoma, Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Other Application.
By End-User:
Based on the End-User, Global Oncolytic Virus Immunotherapy Market is segmented as; Hospitals & Clinics, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-User.
By Region:
This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
According to SPER market research, ‘Global Oncolytic Virus Immunotherapy Market Size- By Virus Type, By Application, By Route of Administration, By End-User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Oncolytic Virus Immunotherapy Market is predicted to reach 2945.34 million by 2034 with a CAGR of 22.85%.
Oncolytic virus immunotherapy refers to the use of viruses in the treatment of cancer, aiming to infect and destroy cells that are affected by the disease. Consequently, the naturally occurring virus is engineered to deliver therapeutic payloads to tumors and provide immune-boosting molecules once tumor cells have been infected. The benefits of oncolytic virus immunotherapy include a reduction in tumor burden through virus replication within tumorous cells.
Restraints:
The substantial expenses associated with oncolytic virus therapy are a critical obstacle impeding the expansion of the global oncolytic virus therapy market. The creation of such therapies necessitates extensive research and prolonged clinical trials, rendering the process exceedingly costly. A significant portion of these expenses arises from the various phases of clinical trials aimed at assessing the efficacy and safety of these therapies in human participants.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered
By Virus Type, By Application, By Route of Administration, By End-User
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Amgen Inc, Creative Biolabs, Daiichi Sankyo Company Limited, Genelux Corporation, Oncorus Inc, Replimune Inc, Siga Technologies, Sorrento Therapeutics Inc, TILT Biotherapeutics, Viralytics Ltd.
Global Oncolytic Virus Immunotherapy Market Segmentation:
By Virus Type:
Based on the Virus Type, Global Oncolytic Virus Immunotherapy Market is segmented as; Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Newcastle Disease Virus, Reovirus, Other Virus Type.
By Route of Administration:
Based on the Route of Administration, Global Oncolytic Virus Immunotherapy Market is segmented as; Intratumoral, Intravenous, Other Routes of Administration.
By Application:
Based on the Application, Global Oncolytic Virus Immunotherapy Market is segmented as; Melanoma, Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Other Application.
By End-User:
Based on the End-User, Global Oncolytic Virus Immunotherapy Market is segmented as; Hospitals & Clinics, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-User.
By Region:
This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
239 Pages
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Oncolytic Virus Immunotherapy Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Oncolytic Virus Immunotherapy Market
- 7. Global Oncolytic Virus Immunotherapy Market, By Virus Type (USD Million) 2021-2034
- 7.1. Herpes Simplex Virus (HSV)
- 7.2. Adenovirus
- 7.3. Vaccinia Virus
- 7.4. Newcastle Disease Virus
- 7.5. Reovirus
- 7.6. Other Virus Type
- 8. Global Oncolytic Virus Immunotherapy Market, By Route of Administration (USD Million) 2021-2034
- 8.1. Intratumoral
- 8.2. Intravenous
- 8.3. Other Routes of Administration
- 9. Global Oncolytic Virus Immunotherapy Market, By Application (USD Million) 2021-2034
- 9.1. Melanoma
- 9.2. Breast Cancer
- 9.3. Lung Cancer
- 9.4. Ovarian Cancer
- 9.5. Prostate Cancer
- 9.6. Other Application
- 10. Global Oncolytic Virus Immunotherapy Market, By End-User (USD Million) 2021-2034
- 10.1. Hospitals & Clinics
- 10.2. Cancer Research Institutes
- 10.3. Ambulatory Surgical Centers
- 10.4. Other End-User
- 11. Global Oncolytic Virus Immunotherapy Market, (USD Million) 2021-2034
- 11.1. Global Oncolytic Virus Immunotherapy Market Size and Market Share
- 12. Global Oncolytic Virus Immunotherapy Market, By Region, (USD Million) 2021-2034
- 12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
- 12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
- 12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
- 12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
- 12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America
- 13. Company Profile
- 13.1. Amgen Inc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
- 13.2. Creative Biolabs
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
- 13.3. Daiichi Sankyo Company Limited
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
- 13.4. Genelux Corporation
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
- 13.5. Oncorus Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
- 13.6. Replimune Inc
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
- 13.7. Siga Technologies
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
- 13.8. Sorrento Therapeutics Inc
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
- 13.9. TILT Biotherapeutics
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
- 13.10. Viralytics Ltd
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
- 13.11. Others
- 14. Conclusion
- 15. List of Abbreviations
- 16. Reference Links
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
